7h agoInvesting.com MarketsBEARISH 42General
Why is Immunovant stock sliding today?
Why is Immunovant stock sliding today?
Archived explainer. For the current picture see today's IMVT page.
Why Is IMMUNOVANT INC (IMVT) Stock Down Today?
By the Top Tier Newswire AI Desk · September 23, 2026 at 10:47 AM ET · reviewed against 8 wire stories
IMMUNOVANT INC (IMVT) is down -7.51% in the latest session. Our newswire has captured 8 stories on IMVT across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 33/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
IMVT stock is down 7.51% at $34.49 as of the latest trade, marking a sharp decline driven by the announcement that its IMVT-1402 lupus study failed to meet its primary endpoint. The company has decided to discontinue development of the drug in cutaneous lupus, though it will continue to explore the therapy for other autoimmune conditions. The stock opened with a -2.9% gap and has since traded lower, reaching a session low of $32.00 before settling near $34.50.
What Happened
Immunovant announced that its 57-patient proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on the primary CLASI-A percent-change endpoint at Week 12. This outcome prompted the company to halt further development of the drug in the indication. The decision has led to a sharp selloff, with the stock falling to over 3-month lows. The move has also drawn attention from market participants, with several news outlets highlighting the trial setback as a key factor behind the stock’s performance.
What The Data Shows
The stock opened at $36.20 and has traded in a wide range, reaching a high of $37.00 and a low of $32.00. Volume has reached 0.8 million shares, which is 0.5 times the 3-month daily average. Over the last 8 sessions, the stock has declined by 5.0% from $38.90 to $36.95. Additionally, the 52-week tape shows 22 fresh 52-week lows and one 52-week high on September 23. Recent insider transactions include 14 sales totaling $4.4 million in the last 90 days, with the most recent sale occurring on August 28.
What To Watch
Investors should monitor Immunovant’s Q1 2027 earnings call, scheduled for later in the year, as well as the broader coverage and sentiment shifts in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IMVT by the numbers
Last: $34.49Session: -7.51%7 sessions: -5.01%Coverage: 8 stories / 7 sourcesAI sentiment: 33/100 (bearish)Mkt cap: $7.6B52w: $14.58 to $45.42
The headlines behind the move
7h agoStocktwits NewsBEARISH 28Product/PR
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.
7h agoInvestorsHubBEARISH 34Earnings
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
Immunovant shares fall 6% after its IMVT-1402 study in cutaneous lupus misses its primary endpoint, prompting the company to end development in the indication.
8h agoMarketChameleonBEARISH 28Product/PR
Immunovant to Halt IMVT-1402 in Cutaneous Lupus After 57-Patient Study Misses Primary CLASI-A Endpoint September 23, 2026
Immunovant said its 57-patient proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on the primary CLASI-A percent-change endpoint at Week 12. Despite numerical trends across multiple endpoints and an observation that deeper IgG reductions were associated with improved clinical responses, the company plans to stop development in CLE while keeping other IMVT-1402 programs on track.
8h agoThe FlyBEARISH 34General
Immunovant announces IMVT-1402 study did not achieve statistical significance
8h agoSeeking AlphaBEARISH 28Product/PR
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Roivant (ROIV) stock and Immunovant (IMVT) stock drop after a trial failure for a drug targeting cutaneous lupus erythematosus. Read more here.
8h agoInvesting.com MarketsBEARISH 32Product/PR
Immunovant stock falls after lupus drug trial misses goal
Immunovant stock falls after lupus drug trial misses goal
8h agoBusiness InsiderBEARISH 34Product/PR
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IMVT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IMVT move explainers: 2026-09-23